Etravirina en pacientes ampliamente pretratados
Etravirine in highly treatment-experienced patients
Daniel Podzamczer Palter
, Elena Ferrer Corbera, Juan Manuel Tiraboschi
Autor para correspondencia
Servicio de Enfermedades Infecciosas, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, España
Leído
2980
Vecesse ha leído el artículo
800
Total PDF
2180
Total HTML
Compartir estadísticas
array:23 [ "pii" => "S0213005X09732136" "issn" => "0213005X" "doi" => "10.1016/S0213-005X(09)73213-6" "estado" => "S300" "fechaPublicacion" => "2009-12-01" "aid" => "73213" "copyright" => "Elsevier España S.L.. Todos los derechos reservados" "copyrightAnyo" => "2009" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Enferm Infecc Microbiol Clin. 2009;27 Supl 2:6-11" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1974 "formatos" => array:3 [ "EPUB" => 9 "HTML" => 1463 "PDF" => 502 ] ] "itemSiguiente" => array:18 [ "pii" => "S0213005X09732148" "issn" => "0213005X" "doi" => "10.1016/S0213-005X(09)73214-8" "estado" => "S300" "fechaPublicacion" => "2009-12-01" "aid" => "73214" "copyright" => "Elsevier España S.L." "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Enferm Infecc Microbiol Clin. 2009;27 Supl 2:12-20" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1995 "formatos" => array:3 [ "EPUB" => 10 "HTML" => 1502 "PDF" => 483 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Etravirina en primeras líneas de tratamiento" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "12" "paginaFinal" => "20" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Etravirine in first-line therapy" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Piedad Arazo Garcés, Esther Valero Tena" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Piedad Arazo" "apellidos" => "Garcés" ] 1 => array:2 [ "nombre" => "Esther Valero" "apellidos" => "Tena" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X09732148?idApp=UINPBA00004N" "url" => "/0213005X/00000027000000S2/v1_201305090145/S0213005X09732148/v1_201305090145/es/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0213005X09732124" "issn" => "0213005X" "doi" => "10.1016/S0213-005X(09)73212-4" "estado" => "S300" "fechaPublicacion" => "2009-12-01" "aid" => "73212" "copyright" => "Elsevier España S.L." "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Enferm Infecc Microbiol Clin. 2009;27 Supl 2:2-5" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2785 "formatos" => array:3 [ "EPUB" => 9 "HTML" => 2142 "PDF" => 634 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Características químicas, mecanismo de acción y actividad antiviral de etravirina" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "2" "paginaFinal" => "5" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Chemical characteristics, mechanism of action and antiviral activity of etravirine" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Federico García García, Marta Álvarez Estévez, Vicente Guillot Suay" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Federico García" "apellidos" => "García" ] 1 => array:2 [ "nombre" => "Marta Álvarez" "apellidos" => "Estévez" ] 2 => array:2 [ "nombre" => "Vicente Guillot" "apellidos" => "Suay" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X09732124?idApp=UINPBA00004N" "url" => "/0213005X/00000027000000S2/v1_201305090145/S0213005X09732124/v1_201305090145/es/main.assets" ] "es" => array:12 [ "idiomaDefecto" => true "titulo" => "Etravirina en pacientes ampliamente pretratados" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "6" "paginaFinal" => "11" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Daniel Podzamczer Palter, Elena Ferrer Corbera, Juan Manuel Tiraboschi" "autores" => array:3 [ 0 => array:4 [ "nombre" => "Daniel Podzamczer" "apellidos" => "Palter" "email" => array:1 [ 0 => "dpodzamczer@bellvitgehospital.cat" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">¿</span>" "identificador" => "cor1" ] ] ] 1 => array:2 [ "nombre" => "Elena Ferrer" "apellidos" => "Corbera" ] 2 => array:2 [ "nombre" => "Juan Manuel" "apellidos" => "Tiraboschi" ] ] "afiliaciones" => array:1 [ 0 => array:1 [ "entidad" => "Servicio de Enfermedades Infecciosas, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, España" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor1" "etiqueta" => "⁎" "correspondencia" => "* Autor para correspondencia." ] ] ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Etravirine in highly treatment-experienced patients" ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec137938" "palabras" => array:4 [ 0 => "Etravirina" 1 => "ITINAN" 2 => "Rescate" 3 => "Multitratados" ] ] ] "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec137937" "palabras" => array:4 [ 0 => "Etravirine" 1 => "NNRTI" 2 => "Rescue" 3 => "Multi-treated" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<p class="elsevierStyleSimplePara elsevierViewall">Etravirina (ETR) se ha mostrado eficaz en pacientes multitratados con fallos virológicos previos y mutaciones de resistencia a varias familias de fármacos antirretrovirales. La mayor evidencia surge de los estudios DUET. Éstos son 2 ensayos clínicos multicéntricos idénticos, aleatorizados y doble ciego, que incluyeron alrededor de 1.200 pacientes, donde se observó una respuesta virológica e inmunológica superior a placebo y que se tradujo en una reducción en la incidencia de ingresos hospitalarios y de progresión a sida/muerte. Además, ETR fue muy bien tolerado en estos pacientes. El efecto adverso más frecuente fue el exantema que, generalmente, fue leve o moderado y únicamente obligó a suspender el tratamiento en el 2% de los pacientes. No hubo diferencias en cuanto a toxicidades gastrointestinales, hepáticas o lipídicas, comparado con la rama placebo.</p><p class="elsevierStyleSimplePara elsevierViewall">El desarrollo reciente de nuevos fármacos permite disponer hoy de pautas activas eficaces para pacientes multitratados. El estudio TRIO ha evaluado la eficacia y tolerabilidad de una de las pautas más utilizadas actualmente en la práctica habitual: ETR/raltegravir/darunavir/r, con excelentes resultados de respuesta virológica e inmunológica (el 86% de carga viral < 50 copias y CD4 +108 a las 48 semanas) y, al mismo tiempo, una muy buena tolerabilidad.</p><p class="elsevierStyleSimplePara elsevierViewall">ETR es eficaz y bien tolerada y es el primer inhibidor de la transcriptasa inversa no análogo de nucleósidos (ITINAN) que permite el uso secuencial de fármacos de esta familia, gracias a su elevada barrera genética comparando con los ITINAN de primera generación. Además, su larga vida media permite su administración una vez al día en caso de que los pacientes necesitaran una pauta qd.</p>" ] "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<p class="elsevierStyleSimplePara elsevierViewall">Etravirine (ETR) has demonstrated efficacy in patients with multiple prior treatments with prior virological failure and resistance mutations to various families of antiretroviral drugs. Most of the evidence concerning this drug has been drawn from the DUET studies, consisting of two multicenter, randomized, double-blind clinical trials with identical designs that included 1,200 patients. These trials showed that ETR obtained a superior virological and immunological response to placebo, reducing the incidence of hospital admissions and progression to AIDS/death. The most frequent adverse effect was rash, which was generally mild to moderate and required treatment discontinuation in only 2%. There were no differences in gastrointestinal, liver or lipid toxicities compared with the placebo arm.</p><p class="elsevierStyleSimplePara elsevierViewall">Because of the recent development of new drugs, effective regimens are now available for multi-treated patients. The TRIO study evaluated the efficacy and tolerability of one of the regimens most widely used today (ETR/raltegravir/darunavir/r) with excellent virological and immunological response (86% of viral load < 50 copies and CD4 +108 at 48 weeks) and excellent tolerance.</p><p class="elsevierStyleSimplePara elsevierViewall">ETR is effective and well tolerated and is the first non-nucleoside reverse transcriptase inhibitor (NNRTI) that allows the sequential use of drugs in this family, due to its high genetic barrier compared with firstgeneration NNRTI. Moreover, its long half-life allows once daily administration in patients requiring a QD regimen.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "Bibliografía" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:25 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Staszewski" 1 => "J. Morales-Ramírez" 2 => "K.T. Tashima" 3 => "A. Rachlis" 4 => "D. Skiest" 5 => "J. Stanford" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJM199912163412501" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "1999" "volumen" => "341" "paginaInicial" => "1865" "paginaFinal" => "1873" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10601505" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Class-sparing regimens for initial treatment of HIV-1 infection" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.A. Riddler" 1 => "R. Haubrich" 2 => "A.G. DiRienzo" 3 => "L. Peeples" 4 => "W.G. Powderly" 5 => "K.L. Klingman" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa074609" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2008" "volumen" => "358" "paginaInicial" => "2095" "paginaFinal" => "3006" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18480202" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A randomized clinical trial comparing nelfinavir or nevirapine associated to ZDV/3TC in HIV-infected naive patients (The Combine Study)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D. Podzamczer" 1 => "E. Ferrer" 2 => "E. Consiglio" 3 => "J.M. Gatell" 4 => "P. Pérez" 5 => "J.L. Pérez" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Antiviral Ther" "fecha" => "2002" "volumen" => "7" "paginaInicial" => "81" "paginaFinal" => "90" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised openlabel trial, the 2NN Study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F. Van Leth" 1 => "P. Phanuphak" 2 => "K. Ruxrungtham" 3 => "E. Baraldi" 4 => "S. Miller" 5 => "B. Gazzard" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Lancet" "fecha" => "2004" "volumen" => "363" "paginaInicial" => "1253" "paginaFinal" => "1263" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Etravirine" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "E.D. Deeks" 1 => "G.M. Keating" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Drugs" "fecha" => "2008" "volumen" => "68" "paginaInicial" => "2357" "paginaFinal" => "2372" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18973398" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pharmacotherapy of HIV: focus on etravirine" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "G. Lapadula" 1 => "A. Soria" 2 => "A. Gori" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clinical Med: Therapeutics" "fecha" => "2009" "volumen" => "1" "paginaInicial" => "483" "paginaFinal" => "494" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "An open-label assessment of TMC 125-a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B.G. Gazzard" 1 => "A.L. Pozniak" 2 => "W. Rosenbaum" 3 => "G.P. Yeni" 4 => "S. Staszewski" 5 => "K. Arasteh" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/01.aids.0000104326.15729.82" "Revista" => array:6 [ "tituloSerie" => "AIDS" "fecha" => "2003" "volumen" => "17" "paginaInicial" => "F49" "paginaFinal" => "54" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14685068" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.P. Nadler" 1 => "D.S. Berger" 2 => "G. Blick" 3 => "P.J. Cimoch" 4 => "C.J. Cohen" 5 => "R.N. Greenberg" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "AIDS" "fecha" => "2007" "volumen" => "21" "paginaInicial" => "F1" "paginaFinal" => "F10" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of etravirine (TMC 125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C.J. Cohen" 1 => "D.S. Berger" 2 => "G. Blick" 3 => "H.A. Grossman" 4 => "D.T. Jayaweera" 5 => "P. Shalit" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/QAD.0b013e32831c5040" "Revista" => array:6 [ "tituloSerie" => "AIDS" "fecha" => "2009" "volumen" => "23" "paginaInicial" => "423" "paginaFinal" => "426" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19114852" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of TMC 125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24 week results from a randomised, double-blind, placebo-controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.V. Madruga" 1 => "P. Cahn" 2 => "B. Grinsztejn" 3 => "R. Haubrich" 4 => "J. Lalezari" 5 => "A. Mills" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(07)61047-2" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2007" "volumen" => "370" "paginaInicial" => "29" "paginaFinal" => "38" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17617270" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of TMC 125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24 week results from a randomised, double-blind, placebo-controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Lazzarin" 1 => "T. Campbell" 2 => "B. Clotet" 3 => "M. Johnson" 4 => "C. Katlama" 5 => "A. Moll" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(07)61048-4" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2007" "volumen" => "370" "paginaInicial" => "39" "paginaFinal" => "48" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17617271" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Duet-1: week- 48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 612 treatment-experienced HIV-1-infected patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Haubrich" 1 => "P. Cahn" 2 => "B. Grinsztejn" 3 => "J. Lalezari" 4 => "J. Madruga" 5 => "A. Mills" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "15th Conference on Retroviruses and Opportunistic Infections" "conferencia" => "Boston" "serieFecha" => "2008" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Durable efficacy and safety of etravirine in treatment- experienced, HIV-1 infected patients: pooled week 96 results from the phase III DUET-1 and DUET-2 trials" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "B. Trottier" 1 => "A. Mills" 2 => "P. Cahn" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:4 [ "titulo" => "18th Annual Canadian Conference on HIV/AIDS Research" "paginaInicial" => "P148" "conferencia" => "Vancouver, Canada" "serieFecha" => "2009" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "48-weeks pooled analysis of DUET-1 and DUET-2 : the impact of baselines characteristics on virologic response to etravirine (TMC125,ETR)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Cahn" 1 => "J.M. Molina" 2 => "W. Towner" 3 => "M. Peeters" 4 => "J. Vingerhoets" 5 => "G. Beets" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "XVII International AIDS Conference" "conferencia" => "México City" "serieFecha" => "2008" ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The impact of background regimen on virological response to etravirine (TMC 125, ETR): pooled 48-week analysis of DUET-1 and DUET-2" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Di Petri" 1 => "J. Valdez Madruga" 2 => "K. Sathasivam" 3 => "M. Peeters" 4 => "J. Vingerhoets" 5 => "C. Corbett" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "XVII International AIDS Conference" "conferencia" => "México City" "serieFecha" => "2008" ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reduction in AIDS-defining events/death with etravirine compared to placebo: pooled DUET 48-week results" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Haubrich" 1 => "J. Eron" 2 => "M. Thompson" 3 => "P. Reiss" 4 => "R. Weber" 5 => "M. Peeters" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "48th Annual ICAAC/IDSA 46th Annual Meeting" "conferencia" => "Washington DC" "serieFecha" => "2008" ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib17" "etiqueta" => "17." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High rate of virologic success with raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: results of the ANRS 139 TRIO trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Y. Yazdanpanah" 1 => "C. Fagard" 2 => "D. Descamps" 3 => "A.M. Taburet" 4 => "B. Roquebert" 5 => "I. Tschope" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "XVII International AIDS Conference" "conferencia" => "México City" "serieFecha" => "2008" ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib18" "etiqueta" => "18." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ARNS 139 TRIO trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Y. Yazdanpanah" 1 => "C. Fagard" 2 => "D. Descamps" 3 => "A.M. Taburet" 4 => "B. Collins" 5 => "B. Roquebert" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2009" "paginaInicial" => "49" ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib19" "etiqueta" => "19." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment response among HIV patients in the etravirine (ETV) and raltegravir (RAL) expanded access program (EAPs) at Kaiser Permanente" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "H. Kerrigan" 1 => "W. Towner" 2 => "S. Follansbee" 3 => "D. Klein" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:3 [ "titulo" => "48th Annual ICAAC/46th Annual IDSA Joint Meeting" "conferencia" => "Washington DC" "serieFecha" => "2008" ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib20" "etiqueta" => "20." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Raltegravir, etravirine and darunavir-ritonavir: a safe and successful rescue regimen in highly treatment-experienced HIV-1-infected patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Imaz" 1 => "S.V. Del Saz" 2 => "M.A. Rivas" 3 => "A. Curran" 4 => "E. Caballero" 5 => "V. Falcó" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "titulo" => "9th International Congress on Drug Therapy in HIV Infection. Glasgow, 11, Suppl 1" "tituloSerie" => "J International AIDS Society" "fecha" => "2008" "paginaInicial" => "40" ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib21" "etiqueta" => "21." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B. Clotet" 1 => "N. Bellos" 2 => "J.M. Molina" 3 => "D. Cooper" 4 => "J.C. Goffard" 5 => "A. Lazzarin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(07)60497-8" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2007" "volumen" => "369" "paginaInicial" => "1169" "paginaFinal" => "1178" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17416261" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib22" "etiqueta" => "22." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B. Ledergerber" 1 => "J.D. Lundgren" 2 => "A.S. Walker" 3 => "C. Sabin" 4 => "A. Justice" 5 => "P. Reiss" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(04)16589-6" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2004" "volumen" => "364" "paginaInicial" => "51" "paginaFinal" => "62" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15234856" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib23" "etiqueta" => "23." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of an antiretroviral regimen containing etravirine plus raltegravir in HIV-1 treatmentexperienced patients failing darunavir" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A. Canestri" 1 => "C. Blanc" 2 => "M. Wirden" 3 => "G. Peytavin" 4 => "N. Ktorza" 5 => "C. Katlama" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "titulo" => "9th International Congress on Drug Therapy in HIV Infection. Glasgow, 11, Suppl 1" "tituloSerie" => "J International AIDS Society" "fecha" => "2008" "paginaInicial" => "38" ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib24" "etiqueta" => "24." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Excellent short term CD4 recovery with a PI-and NNRTI-sparing regimen in triple-class failure HIVinfected patients: raltegravir, maraviroc, etravirine" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Nozza" 1 => "F. Visco" 2 => "A. Soria" 3 => "L. Galli" 4 => "S. Salpietro" 5 => "N. Gianotti" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "titulo" => "9th International Congress on Drug Therapy in HIV Infection. Glasgow, 11, Suppl 1" "tituloSerie" => "J International AIDS Society" "fecha" => "2008" "paginaInicial" => "45" ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib25" "etiqueta" => "25." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Etravirine for the treatment of HIV infection" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:1 [ 0 => "Seminari" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1586/14787210.6.4.427" "Revista" => array:6 [ "tituloSerie" => "Expert Rev Anti Infect Ther" "fecha" => "2008" "volumen" => "6" "paginaInicial" => "427" "paginaFinal" => "433" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18662109" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "es" "url" => "/0213005X/00000027000000S2/v1_201305090145/S0213005X09732136/v1_201305090145/es/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/0213005X/00000027000000S2/v1_201305090145/S0213005X09732136/v1_201305090145/es/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X09732136?idApp=UINPBA00004N" ]
| año/Mes | Html | Total | |
|---|---|---|---|
| 2024 Noviembre | 1 | 0 | 1 |
| 2024 Octubre | 5 | 1 | 6 |
| 2024 Septiembre | 16 | 13 | 29 |
| 2024 Agosto | 15 | 3 | 18 |
| 2024 Julio | 9 | 3 | 12 |
| 2024 Junio | 7 | 6 | 13 |
| 2024 Mayo | 7 | 4 | 11 |
| 2024 Abril | 10 | 3 | 13 |
| 2024 Marzo | 11 | 6 | 17 |
| 2024 Febrero | 5 | 2 | 7 |
| 2024 Enero | 4 | 1 | 5 |
| 2023 Diciembre | 6 | 1 | 7 |
| 2023 Noviembre | 7 | 2 | 9 |
| 2023 Octubre | 7 | 6 | 13 |
| 2023 Septiembre | 5 | 0 | 5 |
| 2023 Agosto | 10 | 1 | 11 |
| 2023 Julio | 3 | 3 | 6 |
| 2023 Junio | 14 | 0 | 14 |
| 2023 Mayo | 33 | 2 | 35 |
| 2023 Abril | 35 | 4 | 39 |
| 2023 Marzo | 16 | 2 | 18 |
| 2023 Febrero | 14 | 2 | 16 |
| 2023 Enero | 9 | 2 | 11 |
| 2022 Diciembre | 6 | 5 | 11 |
| 2022 Noviembre | 17 | 3 | 20 |
| 2022 Octubre | 12 | 7 | 19 |
| 2022 Septiembre | 30 | 14 | 44 |
| 2022 Agosto | 6 | 3 | 9 |
| 2022 Julio | 9 | 6 | 15 |
| 2022 Junio | 23 | 5 | 28 |
| 2022 Mayo | 17 | 7 | 24 |
| 2022 Abril | 7 | 9 | 16 |
| 2022 Marzo | 13 | 7 | 20 |
| 2022 Febrero | 12 | 4 | 16 |
| 2022 Enero | 26 | 9 | 35 |
| 2021 Diciembre | 37 | 8 | 45 |
| 2021 Noviembre | 17 | 9 | 26 |
| 2021 Octubre | 48 | 7 | 55 |
| 2021 Septiembre | 28 | 12 | 40 |
| 2021 Agosto | 31 | 10 | 41 |
| 2021 Julio | 10 | 5 | 15 |
| 2021 Junio | 15 | 7 | 22 |
| 2021 Mayo | 7 | 5 | 12 |
| 2021 Abril | 10 | 13 | 23 |
| 2021 Marzo | 4 | 11 | 15 |
| 2021 Febrero | 7 | 8 | 15 |
| 2021 Enero | 7 | 10 | 17 |
| 2020 Diciembre | 4 | 3 | 7 |
| 2020 Noviembre | 5 | 3 | 8 |
| 2020 Octubre | 6 | 3 | 9 |
| 2020 Septiembre | 8 | 6 | 14 |
| 2020 Agosto | 5 | 5 | 10 |
| 2020 Julio | 3 | 3 | 6 |
| 2020 Junio | 7 | 5 | 12 |
| 2020 Mayo | 5 | 7 | 12 |
| 2020 Abril | 3 | 2 | 5 |
| 2020 Marzo | 12 | 9 | 21 |
| 2020 Febrero | 16 | 3 | 19 |
| 2020 Enero | 14 | 12 | 26 |
| 2019 Diciembre | 8 | 4 | 12 |
| 2019 Noviembre | 3 | 5 | 8 |
| 2019 Octubre | 2 | 6 | 8 |
| 2019 Septiembre | 6 | 8 | 14 |
| 2019 Agosto | 5 | 8 | 13 |
| 2019 Julio | 8 | 15 | 23 |
| 2019 Junio | 18 | 31 | 49 |
| 2019 Mayo | 62 | 28 | 90 |
| 2019 Abril | 31 | 16 | 47 |
| 2019 Marzo | 1 | 6 | 7 |
| 2019 Febrero | 6 | 5 | 11 |
| 2019 Enero | 3 | 3 | 6 |
| 2018 Diciembre | 3 | 5 | 8 |
| 2018 Noviembre | 4 | 6 | 10 |
| 2018 Octubre | 6 | 8 | 14 |
| 2018 Septiembre | 17 | 8 | 25 |
| 2018 Agosto | 4 | 20 | 24 |
| 2018 Julio | 2 | 4 | 6 |
| 2018 Junio | 3 | 9 | 12 |
| 2018 Mayo | 4 | 9 | 13 |
| 2018 Abril | 2 | 5 | 7 |
| 2018 Marzo | 2 | 1 | 3 |
| 2018 Febrero | 8 | 0 | 8 |
| 2018 Enero | 1 | 2 | 3 |
| 2017 Diciembre | 3 | 0 | 3 |
| 2017 Noviembre | 4 | 3 | 7 |
| 2017 Octubre | 9 | 6 | 15 |
| 2017 Septiembre | 5 | 10 | 15 |
| 2017 Agosto | 10 | 0 | 10 |
| 2017 Julio | 7 | 3 | 10 |
| 2017 Junio | 10 | 15 | 25 |
| 2017 Mayo | 11 | 2 | 13 |
| 2017 Abril | 13 | 5 | 18 |
| 2017 Marzo | 18 | 13 | 31 |
| 2017 Febrero | 10 | 3 | 13 |
| 2017 Enero | 7 | 0 | 7 |
| 2016 Diciembre | 12 | 7 | 19 |
| 2016 Noviembre | 26 | 9 | 35 |
| 2016 Octubre | 36 | 3 | 39 |
| 2016 Septiembre | 42 | 7 | 49 |
| 2016 Agosto | 24 | 10 | 34 |
| 2016 Julio | 20 | 2 | 22 |
| 2016 Junio | 13 | 14 | 27 |
| 2016 Mayo | 13 | 7 | 20 |
| 2016 Abril | 21 | 22 | 43 |
| 2016 Marzo | 13 | 5 | 18 |
| 2016 Febrero | 8 | 13 | 21 |
| 2016 Enero | 13 | 8 | 21 |
| 2015 Diciembre | 20 | 9 | 29 |
| 2015 Noviembre | 11 | 5 | 16 |
| 2015 Octubre | 15 | 5 | 20 |
| 2015 Septiembre | 11 | 3 | 14 |
| 2015 Agosto | 6 | 7 | 13 |
| 2015 Julio | 12 | 3 | 15 |
| 2015 Junio | 5 | 3 | 8 |
| 2015 Mayo | 4 | 3 | 7 |
| 2015 Abril | 10 | 11 | 21 |
| 2015 Marzo | 10 | 4 | 14 |
| 2015 Febrero | 9 | 3 | 12 |
| 2015 Enero | 22 | 6 | 28 |
| 2014 Diciembre | 17 | 6 | 23 |
| 2014 Noviembre | 14 | 1 | 15 |
| 2014 Octubre | 19 | 2 | 21 |
| 2014 Septiembre | 21 | 3 | 24 |
| 2014 Agosto | 19 | 3 | 22 |
| 2014 Julio | 28 | 5 | 33 |
| 2014 Junio | 44 | 2 | 46 |
| 2014 Mayo | 21 | 4 | 25 |
| 2014 Abril | 14 | 5 | 19 |
| 2014 Marzo | 14 | 2 | 16 |
| 2014 Febrero | 9 | 1 | 10 |
| 2014 Enero | 11 | 0 | 11 |
| 2013 Diciembre | 12 | 5 | 17 |
| 2013 Noviembre | 22 | 1 | 23 |
| 2013 Octubre | 22 | 4 | 26 |
| 2013 Septiembre | 11 | 1 | 12 |
| 2013 Agosto | 23 | 1 | 24 |
| 2013 Julio | 20 | 1 | 21 |
| 2009 Diciembre | 411 | 0 | 411 |
Mostrar todo
